Premium
British HIV Association guidelines for immunization of HIV‐infected adults 2008
Author(s) -
Geretti AM
Publication year - 2008
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/j.1468-1293.2008.00637.x
Subject(s) - medicine , hepatitis a vaccine , epidemiology , hepatitis b vaccine , vaccination , hiv vaccine , immunization , hepatitis a , cholera vaccine , hepatitis b , pre exposure prophylaxis , diphtheria , pediatrics , immunology , virology , human immunodeficiency virus (hiv) , hepatitis , hepatitis b virus , hbsag , men who have sex with men , antibody , vaccine trial , virus , genetics , syphilis , biology , bacteria , vibrio cholerae
Table of contents 1.0 Introduction 1.1 General principles of immunization in HIVinfected adults 1.2 Practical aspects of immunization and general contraindication 2.0 Anthrax 2.1 Background 2.2 Epidemiology and risk groups 2.3 Anthrax vaccine 2.3.1 Vaccine efficacy 2.3.2 Vaccine safety 2.4 Recommendations for anthrax pre-exposure prophylaxis in HIV-infected adults 2.5 Post-exposure prophylaxis 3.0 Cholera 3.1 Background 3.2 Epidemiology and risk groups 3.3 Cholera vaccine 3.3.1 Vaccine efficacy 3.3.2 Vaccine safety 3.3.3 Contraindications 3.4 Recommendations for cholera pre-exposure prophylaxis in HIV-infected adults 4.0 Diphtheria 4.1 Background 4.2 Epidemiology and risk groups 4.3 Diphtheria vaccine 4.3.1 Vaccine efficacy 4.3.2 Vaccine safety 4.4 Recommendations for diphtheria pre-exposure prophylaxis in HIV-infected adults 4.5 Post-exposure prophylaxis 4.6 Auditable outcomes 5.0 Haemophilus influenzae serotype b 5.1 Background 5.2 Epidemiology and risk groups 5.3 Hib vaccine 5.3.1 Vaccine efficacy 5.3.2 Vaccine safety 5.4 Recommendations for H. influenzae pre-exposure prophylaxis in HIV-infected adults 5.5 Post-exposure prophylaxis 5.6 Auditable outcomes 6.0 Hepatitis A 6.1 Background 6.2 Epidemiology and risk groups 6.3 Hepatitis A vaccine 6.3.1 Vaccine efficacy 6.3.2 Vaccine safety 6.4 Human normal immunoglobulin 6.5 Recommendations for hepatitis A pre-exposure prophylaxis in HIV-infected adults 6.6 Post-exposure prophylaxis 6.7 Recommendations for hepatitis A post-exposure prophylaxis in HIV-infected adults 6.8 Auditable outcomes 7.0 Hepatitis B 7.1 Background 7.2 Epidemiology and risk groups 7.3 Hepatitis B vaccine 7.3.1 Vaccine efficacy 7.3.2 Vaccine safety 7.4 Recommendations for hepatitis B pre-exposure prophylaxis in HIV-infected adults 7.5 Post-exposure prophylaxis *Anna Maria Geretti, Royal Free Hospital, London; Gary Brook, Central Middlesex Hospital, London; Claire Cameron, Health Protection Agency, Colindale; David Chadwick, James Cook University Hospital, Middlesbrough; Robert S Heyderman, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi; Eithne MacMahon, Guy’s and St Thomas’ NHS Foundation Trust, London; Anton Pozniak, Chelsea and Westminster Hospital, London; Mary Ramsay, Health Protection Agency, Colindale; M Schuhwerk, Mortimer Market Centre, London.